Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule IV
- 250mg
- 350mg
Musculoskeletal Conditions
250-350 mg q8hr and HS; not to exceed 2-3 weeks; taper slowly (over 14 days) in patients with history of long term use to avoid withdrawal symptoms, including insomnia, anxiety, or irritability
Dosing Modifications
Renal impairment: Caution; not studied
Hepatic impairment: Caution; not studied
Dosage Forms & Strengths
tablet: Schedule IV
- 250mg
- 350mg
Musculoskeletal Conditions
<16 years: Not recommended
>16 years: 250-350 mg q8hr and HS; not to exceed 2-3 weeks; taper slowly (over 14 days) in patients with history of long term use to avoid withdrawal symptoms, including insomnia, anxiety, or irritability
Not drug of choice in elderly, owing to risk of orthostatic hypotension and CNS depression
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (10)
- apalutamide
apalutamide will decrease the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- calcium/magnesium/potassium/sodium oxybates
carisoprodol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- hydrocodone
hydrocodone, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- lonafarnib
lonafarnib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling.
- metoclopramide intranasal
carisoprodol, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
carisoprodol and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- selinexor
selinexor, carisoprodol. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sodium oxybate
carisoprodol, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- sufentanil SL
sufentanil SL, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
Monitor Closely (168)
- abobotulinumtoxinA
carisoprodol increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- acrivastine
acrivastine and carisoprodol both increase sedation. Use Caution/Monitor.
- alfentanil
carisoprodol and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
alprazolam and carisoprodol both increase sedation. Use Caution/Monitor.
- amisulpride
amisulpride and carisoprodol both increase sedation. Use Caution/Monitor.
- amitriptyline
carisoprodol and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
amobarbital and carisoprodol both increase sedation. Use Caution/Monitor.
- amoxapine
carisoprodol and amoxapine both increase sedation. Use Caution/Monitor.
- apomorphine
carisoprodol and apomorphine both increase sedation. Use Caution/Monitor.
- aripiprazole
carisoprodol and aripiprazole both increase sedation. Use Caution/Monitor.
- asenapine
asenapine and carisoprodol both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and carisoprodol both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and carisoprodol both increase sedation. Use Caution/Monitor.
- baclofen
baclofen and carisoprodol both increase sedation. Use Caution/Monitor.
- belladonna and opium
carisoprodol and belladonna and opium both increase sedation. Use Caution/Monitor.
- benperidol
carisoprodol and benperidol both increase sedation. Use Caution/Monitor.
- benzphetamine
carisoprodol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexanolone
brexanolone, carisoprodol. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and carisoprodol both increase sedation. Use Caution/Monitor.
- buprenorphine
carisoprodol and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
carisoprodol and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection increases effects of carisoprodol by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary.
- butabarbital
butabarbital and carisoprodol both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and carisoprodol both increase sedation. Use Caution/Monitor.
- butorphanol
carisoprodol and butorphanol both increase sedation. Use Caution/Monitor.
- cannabidiol
cannabidiol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol.
- carbinoxamine
carbinoxamine and carisoprodol both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider a dose reduction of CYP2C19 substrates, as clinically appropriate, when used concomitantly with cenobamate.
cenobamate, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. - chloral hydrate
chloral hydrate and carisoprodol both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and carisoprodol both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.
- chlorpromazine
carisoprodol and chlorpromazine both increase sedation. Use Caution/Monitor.
- cinnarizine
cinnarizine and carisoprodol both increase sedation. Use Caution/Monitor.
- clemastine
clemastine and carisoprodol both increase sedation. Use Caution/Monitor.
- clobazam
carisoprodol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
carisoprodol and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
clonazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- clorazepate
clorazepate and carisoprodol both increase sedation. Use Caution/Monitor.
- clozapine
carisoprodol and clozapine both increase sedation. Use Caution/Monitor.
- codeine
carisoprodol and codeine both increase sedation. Use Caution/Monitor.
- cyclizine
cyclizine and carisoprodol both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
carisoprodol and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
cyproheptadine and carisoprodol both increase sedation. Use Caution/Monitor.
- dantrolene
carisoprodol and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
carisoprodol and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- desipramine
carisoprodol and desipramine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
dexchlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.
- dexfenfluramine
carisoprodol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
dexmedetomidine and carisoprodol both increase sedation. Use Caution/Monitor.
- dextromoramide
carisoprodol and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
carisoprodol and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- difelikefalin
difelikefalin and carisoprodol both increase sedation. Use Caution/Monitor.
- difenoxin hcl
carisoprodol and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and carisoprodol both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and carisoprodol both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
carisoprodol and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
carisoprodol and dipipanone both increase sedation. Use Caution/Monitor.
- dopexamine
carisoprodol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
carisoprodol and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
carisoprodol and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
doxylamine and carisoprodol both increase sedation. Use Caution/Monitor.
- droperidol
carisoprodol and droperidol both increase sedation. Use Caution/Monitor.
- elagolix
elagolix will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.
- esketamine intranasal
esketamine intranasal, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- eslicarbazepine acetate
eslicarbazepine acetate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
- estazolam
estazolam and carisoprodol both increase sedation. Use Caution/Monitor.
- ethanol
carisoprodol and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and carisoprodol both increase sedation. Use Caution/Monitor.
- fedratinib
fedratinib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.
- fenfluramine
carisoprodol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fexinidazole
fexinidazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
- fluphenazine
carisoprodol and fluphenazine both increase sedation. Use Caution/Monitor.
- flurazepam
flurazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- ganaxolone
carisoprodol and ganaxolone both increase sedation. Use Caution/Monitor.
- haloperidol
carisoprodol and haloperidol both increase sedation. Use Caution/Monitor.
- hydromorphone
carisoprodol and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and carisoprodol both increase sedation. Use Caution/Monitor.
- iloperidone
carisoprodol and iloperidone both increase sedation. Use Caution/Monitor.
- imipramine
carisoprodol and imipramine both increase sedation. Use Caution/Monitor.
- incobotulinumtoxinA
carisoprodol, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- ketamine
ketamine and carisoprodol both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
carisoprodol and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, carisoprodol. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levorphanol
carisoprodol and levorphanol both increase sedation. Use Caution/Monitor.
- lofepramine
carisoprodol and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
carisoprodol and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
loprazolam and carisoprodol both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- lormetazepam
lormetazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- loxapine
carisoprodol and loxapine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
carisoprodol and loxapine inhaled both increase sedation. Use Caution/Monitor.
- lumacaftor/ivacaftor
lumacaftor/ivacaftor, carisoprodol. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .
- lurasidone
lurasidone, carisoprodol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
carisoprodol and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
carisoprodol and marijuana both increase sedation. Use Caution/Monitor.
- melatonin
carisoprodol and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
carisoprodol and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
carisoprodol and meprobamate both increase sedation. Use Caution/Monitor.
- metaxalone
carisoprodol and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
carisoprodol and methadone both increase sedation. Use Caution/Monitor.
- methocarbamol
carisoprodol and methocarbamol both increase sedation. Use Caution/Monitor.
- methylenedioxymethamphetamine
carisoprodol increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midazolam
midazolam and carisoprodol both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- mirtazapine
carisoprodol and mirtazapine both increase sedation. Use Caution/Monitor.
- morphine
carisoprodol and morphine both increase sedation. Use Caution/Monitor.
- motherwort
carisoprodol and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
carisoprodol and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
carisoprodol and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
carisoprodol and nalbuphine both increase sedation. Use Caution/Monitor.
- nortriptyline
carisoprodol and nortriptyline both increase sedation. Use Caution/Monitor.
- olanzapine
carisoprodol and olanzapine both increase sedation. Use Caution/Monitor.
- oliceridine
oliceridine, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
carisoprodol increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics. - ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)
ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) decreases effects of carisoprodol by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Increase dose if clinically indicated.
- opium tincture
carisoprodol and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
carisoprodol and orphenadrine both increase sedation. Use Caution/Monitor.
- oxazepam
oxazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- oxycodone
carisoprodol and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
carisoprodol and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
carisoprodol and paliperidone both increase sedation. Use Caution/Monitor.
- papaveretum
carisoprodol and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
carisoprodol and papaverine both increase sedation. Use Caution/Monitor.
- pentazocine
carisoprodol and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
pentobarbital and carisoprodol both increase sedation. Use Caution/Monitor.
- perphenazine
carisoprodol and perphenazine both increase sedation. Use Caution/Monitor.
- phenobarbital
phenobarbital and carisoprodol both increase sedation. Use Caution/Monitor.
- phenylephrine PO
carisoprodol increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
carisoprodol and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
carisoprodol and pimozide both increase sedation. Use Caution/Monitor.
- prabotulinumtoxinA
carisoprodol increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- primidone
primidone and carisoprodol both increase sedation. Use Caution/Monitor.
- prochlorperazine
carisoprodol and prochlorperazine both increase sedation. Use Caution/Monitor.
- promethazine
promethazine and carisoprodol both increase sedation. Use Caution/Monitor.
- propofol
propofol and carisoprodol both increase sedation. Use Caution/Monitor.
- propylhexedrine
carisoprodol increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
carisoprodol and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
quazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- quetiapine
carisoprodol and quetiapine both increase sedation. Use Caution/Monitor.
- ramelteon
carisoprodol and ramelteon both increase sedation. Use Caution/Monitor.
- remimazolam
remimazolam, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
- risperidone
carisoprodol and risperidone both increase sedation. Use Caution/Monitor.
- rucaparib
rucaparib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP2C19 substrates, if clinically indicated.
- scullcap
carisoprodol and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and carisoprodol both increase sedation. Use Caution/Monitor.
- shepherd's purse
carisoprodol and shepherd's purse both increase sedation. Use Caution/Monitor.
- sparsentan
sparsentan will decrease the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates.
- stiripentol
stiripentol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.
stiripentol, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. Concurrent use of medications with CNS depressant effects together with thalidomide should be avoided due to the risk for additive sedative effects. - sufentanil
carisoprodol and sufentanil both increase sedation. Use Caution/Monitor.
- tapentadol
carisoprodol and tapentadol both increase sedation. Use Caution/Monitor.
- tecovirimat
tecovirimat will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.
- temazepam
temazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- thioridazine
carisoprodol and thioridazine both increase sedation. Use Caution/Monitor.
- thiothixene
carisoprodol and thiothixene both increase sedation. Use Caution/Monitor.
- topiramate
carisoprodol and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
carisoprodol and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
carisoprodol and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
triazolam and carisoprodol both increase sedation. Use Caution/Monitor.
- triclabendazole
triclabendazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.
- triclofos
triclofos and carisoprodol both increase sedation. Use Caution/Monitor.
- trifluoperazine
carisoprodol and trifluoperazine both increase sedation. Use Caution/Monitor.
- trimipramine
carisoprodol and trimipramine both increase sedation. Use Caution/Monitor.
- xylometazoline
carisoprodol increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
carisoprodol and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
carisoprodol and ziprasidone both increase sedation. Use Caution/Monitor.
- zotepine
carisoprodol and zotepine both increase sedation. Use Caution/Monitor.
Minor (2)
- eucalyptus
carisoprodol and eucalyptus both increase sedation. Minor/Significance Unknown.
- sage
carisoprodol and sage both increase sedation. Minor/Significance Unknown.
Adverse Effects
>10%
Drowsiness (13-17%)
1-10%
Dizziness (7-8%)
Headache (3-5%)
Frequency Not Defined
Orthostatic hypotension
Syncope
Tachycardia
Agitation
Irritability
Depression
Allergic/idiosyncratic reactions (pruritus, rash, dizziness, etc)
Epigastric distress
N/V
Facial flushing
Weakness
Warnings
Contraindications
Hypersensitivity to carisoprodol, meprobamate, mebutamate, tybamate
History of acute intermittent porphyria
Cautions
Caution in hepatic/renal impairment
May cause CNS depression; use caution when performing tasks which require mental alertness (eg, operating heavy machinery); sedating effects potentiated when used with other CNS-depressant drugs or ethanol
Severe weakness may occur
Seizures reported with its use in patients with or without seizure history
Risk of allergic reactions
Use caution in patients with history of drug abuse or acute alcoholism; drug dependency may occur and withdrawal symptoms experienced with abrupt cessation, especially with long-term use; limit use to 2-3 weeks
Pregnancy & Lactation
Pregnancy
Data over many decades of use of drug in pregnancy have not identified drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes; data on meprobamate, the primary metabolite of carisoprodol, do not show consistent association between maternal use and increased risk of major birth defects
Animal data
- In a published animal reproduction study, pregnant mice administered carisoprodol orally at 2.6- and 4.1-times maximum recommended human dose of 1400 mg per day [350 mg QID] based on body surface area comparison) from gestation through weaning resulted in reduced fetal weights, postnatal weight gain, and postnatal survival
Lactation
Data from published literature report that carisoprodol and its metabolite, meprobamate, are present in breastmilk; there are no data on effect on milk production; there is one report of sedation in an infant who was breastfed by a mother taking carisoprodol; because there have been no consistent reports of adverse events in breastfed infants over decades of use, the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant or from underlying maternal condition; infants exposed to drug through breast milk should be monitored for sedation
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Not clearly known; may block interneural activity and depress polysynaptic neuron transmission
Absorption
Onset: 30 min
Duration: 4-6 hr
Peak plasma time: 1.5-2 hr
Metabolism
Metabolized by liver microsomal enzymes (CYP2C19)
Elimination
Half-life: 2 hr; meprobamate (8 hr)
Dialyzable: Yes (HD, PD)
Excretion: Urine
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 250 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 350 mg tablet |  | |
| carisoprodol oral - | 250 mg tablet |  | |
| carisoprodol oral - | 250 mg tablet |  | |
| carisoprodol oral - | 250 mg tablet |  | |
| Soma oral - | 350 mg tablet |  | |
| Soma oral - | 250 mg tablet |  | |
| Soma oral - | 350 mg tablet |  | |
| Vanadom oral - | 350 mg tablet | |
Copyright © 2010 First DataBank, Inc.
Patient Handout
carisoprodol oral
CARISOPRODOL - ORAL
(kar-iss-oh-PRO-dole)
COMMON BRAND NAME(S): Soma
USES: Carisoprodol is used short-term to treat muscle pain and discomfort. It is usually used along with rest, physical therapy, and other treatments. It works by helping to relax the muscles.
HOW TO USE: Take this medication by mouth with or without food as directed by your doctor. Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase.The dosage is based on your medical condition and response to treatment. This medication should only be used short-term (for 3 weeks or less) unless directed by your doctor.If you suddenly stop using this medication, you may have withdrawal symptoms (such as stomach cramps, trouble sleeping, headache, nausea). To help prevent withdrawal, your doctor may lower your dose slowly. Withdrawal is more likely if you have used carisoprodol for a long time or in high doses. Tell your doctor or pharmacist right away if you have withdrawal.Though it helps many people, this medication may sometimes cause addiction. This risk may be higher if you have a substance use disorder (such as overuse of or addiction to drugs/alcohol). Take this medication exactly as prescribed to lower the risk of addiction. Ask your doctor or pharmacist for more details.Tell your doctor if your condition lasts after 2 to 3 weeks or if it gets worse.
SIDE EFFECTS: Dizziness, drowsiness, or headache may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: confusion.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking carisoprodol, tell your doctor or pharmacist if you are allergic to it; or to meprobamate, tybamate, or mebutamate; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: a certain blood disorder (acute intermittent porphyria), kidney disease, liver disease, seizure, personal or family history of a substance use disorder (such as overuse of or addiction to drugs/alcohol).This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially drowsiness, or confusion. These side effects can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), other muscle relaxants (such as cyclobenzaprine, methocarbamol), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness/dizziness, seizures, slow/shallow breathing, mental/mood changes (such as confusion, hallucinations), inability to move your legs/arms, shaky/unsteady movement, vision changes (such as blurred vision).
NOTES: Do not share this medication with others. Sharing it is against the law.This medication has been prescribed for your current condition only. Do not use it later for another condition unless your doctor directs you to do so. A different medication may be necessary in that case.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised March 2022. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
